{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:40:49Z","timestamp":1767141649620,"version":"build-2238731810"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["T32-CA009529"],"award-info":[{"award-number":["T32-CA009529"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006545","name":"National Institute on Minority Health and Health Disparities","doi-asserted-by":"publisher","award":["1R01MD011506"],"award-info":[{"award-number":["1R01MD011506"]}],"id":[{"id":"10.13039\/100006545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000142","name":"Avon Foundation for Women","doi-asserted-by":"publisher","award":["01-2015-069"],"award-info":[{"award-number":["01-2015-069"]}],"id":[{"id":"10.13039\/100000142","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Causes Control"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s10552-021-01530-1","type":"journal-article","created":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T19:03:47Z","timestamp":1642014227000},"page":"363-371","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Current regular aspirin use and mammographic breast density: a cross-sectional analysis considering concurrent statin and metformin use"],"prefix":"10.1007","volume":"33","author":[{"given":"Teofilia","family":"Acheampong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica J.","family":"Lee Argov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Beth","family":"Terry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen B.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariangela","family":"Agovino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shweta","family":"Athilat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0605-3934","authenticated-orcid":false,"given":"Parisa","family":"Tehranifar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,13]]},"reference":[{"key":"1530_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/CAAC.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/CAAC.21660","journal-title":"CA Cancer J Clin"},{"key":"1530_CR2","doi-asserted-by":"crossref","unstructured":"Howell A, Anderson AS, Clarke RB, Duffy SW, Evans DG, Garcia-Closas M, et al. Risk determination and prevention of breast cancer. Breast Cancer Res. 2014;16.","DOI":"10.1186\/s13058-014-0446-2"},{"key":"1530_CR3","doi-asserted-by":"publisher","first-page":"5578","DOI":"10.18632\/oncotarget.13484","volume":"8","author":"MS Shawky","year":"2017","unstructured":"Shawky MS, Martin H, Hugo HJ, Lloyd T, Britt KL, Redfern A et al (2017) Mammographic density: a potential monitoring biomarker for adjuvant and preventative breast cancer endocrine therapies. Oncotarget 8:5578\u20135591","journal-title":"Oncotarget"},{"key":"1530_CR4","doi-asserted-by":"crossref","unstructured":"Eriksson L, He W, Eriksson M, Humphreys K, Bergh J, Hall P, et al. Adjuvant Therapy and Mammographic Density Changes in Women With Breast Cancer. JNCI Cancer Spectr. 2018;2.","DOI":"10.1093\/jncics\/pky071"},{"key":"1530_CR5","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3322\/caac.21225","volume":"64","author":"GA Colditz","year":"2014","unstructured":"Colditz GA, Bohlke K (2014) Priorities for the primary prevention of breast cancer. CA Cancer J Clin 64:186\u2013194. https:\/\/doi.org\/10.3322\/caac.21225","journal-title":"CA Cancer J Clin"},{"key":"1530_CR6","doi-asserted-by":"crossref","unstructured":"Holmes MD, Chen WY. Hiding in plain view: the potential for commonly used drugs to reduce breast cancer mortality. Breast Cancer Research. 2012;14.","DOI":"10.1186\/bcr3336"},{"key":"1530_CR7","doi-asserted-by":"crossref","unstructured":"Mocellin S, Pilati P, Briarava M, Nitti D. Breast Cancer Chemoprevention: a Network Meta-Analysis of Randomized Controlled Trials. Journal of the National Cancer Institute. 2016;108.","DOI":"10.1093\/jnci\/djv318"},{"key":"1530_CR8","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s10549-011-1747-0","volume":"131","author":"T Luo","year":"2012","unstructured":"Luo T, Yan HM, He P, Luo Y, Yang YF, Zheng H (2012) Aspirin use and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 131:581\u2013587. https:\/\/doi.org\/10.1007\/s10549-011-1747-0","journal-title":"Breast Cancer Res Treat"},{"key":"1530_CR9","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000021917","volume":"99","author":"Y Cao","year":"2020","unstructured":"Cao Y, Tan A (2020) Aspirin might reduce the incidence of breast cancer: an updated meta-analysis of 38 observational studies. Medicine (Baltimore) 99:e21917. https:\/\/doi.org\/10.1097\/MD.0000000000021917","journal-title":"Medicine (Baltimore)"},{"key":"1530_CR10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.breast.2010.07.004","volume":"20","author":"V Ashok","year":"2011","unstructured":"Ashok V, Dash C, Rohan TE, Sprafka JM, Terry PD (2011) Selective cyclooxygenase-2 (COX-2) inhibitors and breast cancer risk. Breast 20:66\u201370. https:\/\/doi.org\/10.1016\/j.breast.2010.07.004","journal-title":"Breast"},{"key":"1530_CR11","doi-asserted-by":"crossref","unstructured":"Rashid S, Rashid S. Major mediators linking inflammation and cancer. In: Cancer and chemoprevention: an overview. Springer Singapore; 2017. p. 35\u201345.","DOI":"10.1007\/978-981-10-2579-2_8"},{"key":"1530_CR12","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1210\/jc.2004-2029","volume":"90","author":"ES Diaz-Cruz","year":"2005","unstructured":"Diaz-Cruz ES, Shapiro CL, Brueggemeier RW (2005) Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. J Clin Endocrinol Metab 90:2563\u20132570. https:\/\/doi.org\/10.1210\/jc.2004-2029","journal-title":"J Clin Endocrinol Metab"},{"key":"1530_CR13","doi-asserted-by":"crossref","unstructured":"Zhang X, Smith-Warner SA, Collins LC, Rosner B, Willett WC, Hankinson SE. Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and postmenopausal breast cancer incidence. 2012;30:3468\u201377.","DOI":"10.1200\/JCO.2012.42.2006"},{"key":"1530_CR14","doi-asserted-by":"publisher","first-page":"40389","DOI":"10.18632\/oncotarget.16315","volume":"8","author":"L Lu","year":"2017","unstructured":"Lu L, Shi L, Zeng J, Wen Z (2017) Aspirin as a potential modality for the chemoprevention of breast cancer: a dose-response meta-analysis of cohort studies from 857,831 participants. Oncotarget 8:40389\u201340401. https:\/\/doi.org\/10.18632\/oncotarget.16315","journal-title":"Oncotarget"},{"key":"1530_CR15","doi-asserted-by":"crossref","unstructured":"Kehm RD, Hopper JL, John EM, Phillips KA, MacInnis RJ, Dite GS, et al. Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: a cohort study. Breast Cancer Res. 2019;21.","DOI":"10.1186\/s13058-019-1135-y"},{"key":"1530_CR16","doi-asserted-by":"crossref","unstructured":"Ma S, Guo C, Sun C, Han T, Zhang H, Qu G, et al. Aspirin use and risk of breast cancer: a meta-analysis of observational studies from 1989 to 2019. Clin Breast Cancer. 2021.","DOI":"10.1016\/j.clbc.2021.02.005"},{"key":"1530_CR17","doi-asserted-by":"crossref","unstructured":"Cairat M, Al Rahmoun M, Gunter MJ, Severi G, Dossus L, Fournier A. Use of nonsteroidal anti-inflammatory drugs and breast cancer risk in a prospective cohort of postmenopausal women. Breast Cancer Res. 2020;22.","DOI":"10.1186\/s13058-020-01343-1"},{"key":"1530_CR18","doi-asserted-by":"crossref","unstructured":"Bertrand KA, Bethea TN, Gerlovin H, Coogan PF, Barber L, Rosenberg L, et al. Aspirin use and risk of breast cancer in African American women. Breast Cancer Res. 2020;22.","DOI":"10.1186\/s13058-020-01335-1"},{"key":"1530_CR19","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1158\/1055-9965.EPI-06-0034","volume":"15","author":"VA McCormack","year":"2006","unstructured":"McCormack VA, dos Santos SI (2006) Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 15:1159\u20131169. https:\/\/doi.org\/10.1158\/1055-9965.EPI-06-0034","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"1530_CR20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13058-016-0701-9","volume":"18","author":"MJ Sherratt","year":"2016","unstructured":"Sherratt MJ, McConnell JC, Streuli CH (2016) Raised mammographic density: causative mechanisms and biological consequences. Breast Cancer Res 18:45. https:\/\/doi.org\/10.1186\/s13058-016-0701-9","journal-title":"Breast Cancer Res"},{"key":"1530_CR21","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/jnci\/87.9.670","volume":"87","author":"NF Boyd","year":"1995","unstructured":"Boyd NF, Byng JW, Jong RA, Fishell EK, Little LE, Miller AB et al (1995) Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian national breast screening study. JNCI J Natl Cancer Inst 87:670\u2013675. https:\/\/doi.org\/10.1093\/jnci\/87.9.670","journal-title":"JNCI J Natl Cancer Inst"},{"key":"1530_CR22","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1023\/A:1008926607428","volume":"11","author":"CM Vachon","year":"2000","unstructured":"Vachon CM, Kuni CC, Anderson K, Anderson VE, Sellers TA (2000) Association of mammographically defined percent breast density with epidemiologic risk factors for breast cancer (United States). Cancer Causes Control 11:653\u2013662. https:\/\/doi.org\/10.1023\/A:1008926607428","journal-title":"Cancer Causes Control"},{"key":"1530_CR23","doi-asserted-by":"crossref","unstructured":"Boyd NF, Lockwood GA, Byng JW, Tritchler DL, Yaffe MJ. Mammographic densities and breast cancer risk. Cancer Epidemiol Prev Biomarkers. 1998;7.","DOI":"10.3233\/BD-1998-103-412"},{"key":"1530_CR24","doi-asserted-by":"crossref","unstructured":"Nyante SJ, Sherman ME, Pfeiffer RM, Berrington De Gonzalez A, Brinton LA, Aiello Bowles EJ, et al. Longitudinal change in mammographic density among ER-positive breast cancer patients using tamoxifen. Cancer Epidemiol Biomarkers Prev. 2016;25:212\u20136.","DOI":"10.1158\/1055-9965.EPI-15-0412"},{"key":"1530_CR25","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1158\/1055-9965.EPI-16-0882","volume":"26","author":"NJ Engmann","year":"2017","unstructured":"Engmann NJ, Scott CG, Jensen MR, Ma L, Brandt KR, Mahmoudzadeh AP et al (2017) Longitudinal changes in volumetric breast density with tamoxifen and aromatase inhibitors. Cancer Epidemiol Biomarkers Prev 26:930\u2013937","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"1530_CR26","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s10549-020-05744-w","volume":"182","author":"S Azam","year":"2020","unstructured":"Azam S, Jacobsen KK, Aro AR, Lynge E, Andersen ZJ (2020) Hormone replacement therapy and mammographic density: a systematic literature review. Breast Cancer Res Treat 182:555\u2013579","journal-title":"Breast Cancer Res Treat"},{"key":"1530_CR27","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s10549-011-1834-2","volume":"132","author":"J Stone","year":"2012","unstructured":"Stone J, Willenberg L, Apicella C, Treloar S, Hopper J (2012) The association between mammographic density measures and aspirin or other NSAID use. Breast Cancer Res Treat 132:259\u2013266. https:\/\/doi.org\/10.1007\/s10549-011-1834-2","journal-title":"Breast Cancer Res Treat"},{"key":"1530_CR28","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1158\/1055-9965.EPI-08-1088","volume":"18","author":"A McTiernan","year":"2009","unstructured":"McTiernan A, Wang CY, Sorensen B, Xiao L, Buist DSM, Aiello Bowles EJ et al (2009) No effect of aspirin on mammographic density in a randomized controlled clinical trial. Cancer Epidemiol Biomarkers Prev 18:1524\u20131530. https:\/\/doi.org\/10.1158\/1055-9965.EPI-08-1088","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"1530_CR29","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1158\/1055-9965.EPI-07-2836","volume":"17","author":"MB Terry","year":"2008","unstructured":"Terry MB, Buist DSM, Trentham-Dietz A, James-Todd TM, Liao Y (2008) Nonsteroidal anti-inflammatory drugs and change in mammographic density: a cohort study using pharmacy records on over 29,000 postmenopausal women. Cancer Epidemiol Biomarkers Prev 17:1088\u20131095. https:\/\/doi.org\/10.1158\/1055-9965.EPI-07-2836","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"1530_CR30","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s10549-017-4127-6","volume":"162","author":"ME Wood","year":"2017","unstructured":"Wood ME, Sprague BL, Oustimov A, Synnstvedt MB, Cuke M, Conant EF et al (2017) Aspirin use is associated with lower mammographic density in a large screening cohort. Breast Cancer Res Treat 162:419\u2013425. https:\/\/doi.org\/10.1007\/s10549-017-4127-6","journal-title":"Breast Cancer Res Treat"},{"key":"1530_CR31","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10549-007-9829-8","volume":"112","author":"G Maskarinec","year":"2008","unstructured":"Maskarinec G, Urano Y, Gill J, Kolonel LN (2008) Nonsteroidal anti-inflammatory drugs (NSAIDs) and mammographic density. Breast Cancer Res Treat 112:133\u2013139. https:\/\/doi.org\/10.1007\/s10549-007-9829-8","journal-title":"Breast Cancer Res Treat"},{"key":"1530_CR32","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s10552-020-01321-0","volume":"31","author":"L Yaghjyan","year":"2020","unstructured":"Yaghjyan L, Wijayabahu A, Eliassen AH, Colditz G, Rosner B, Tamimi RM (2020) Associations of aspirin and other anti-inflammatory medications with mammographic breast density and breast cancer risk. Cancer Causes Control 31:827\u2013837","journal-title":"Cancer Causes Control"},{"key":"1530_CR33","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s10549-014-3030-7","volume":"146","author":"Y Cui","year":"2014","unstructured":"Cui Y, Deming-Halverson SL, Shrubsole MJ, Beeghly-Fadiel A, Cai H, Fair AM et al (2014) Use of nonsteroidal anti-inflammatory drugs and reduced breast cancer risk among overweight women. Breast Cancer Res Treat 146:439\u2013446","journal-title":"Breast Cancer Res Treat"},{"key":"1530_CR34","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/bjc.2015.259","volume":"113","author":"MMJ Zanders","year":"2015","unstructured":"Zanders MMJ, van Herk-Sukel MPP, Vissers PAJ, Herings RMC, Haak HR, van de Poll-Franse LV (2015) Are metformin, statin and aspirin use still associated with overall mortality among colorectal cancer patients with diabetes if adjusted for one another? Br J Cancer 113:403\u2013410","journal-title":"Br J Cancer"},{"key":"1530_CR35","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1158\/1055-9965.EPI-17-0885","volume":"27","author":"P Tehranifar","year":"2018","unstructured":"Tehranifar P, Rodriguez CB, April-Sanders AK, Desperito E, Schmitt KM (2018) Migration history, language acculturation, and mammographic breast density. Cancer Epidemiol Biomarkers Prev 27:566\u2013574. https:\/\/doi.org\/10.1158\/1055-9965.EPI-17-0885","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"1530_CR36","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s10552-015-0630-4","volume":"26","author":"P Tehranifar","year":"2015","unstructured":"Tehranifar P, Protacio A, Schmitt KM, Desperito E, Oskar S, Potter AJ et al (2015) The metabolic syndrome and mammographic breast density in a racially diverse and predominantly immigrant sample of women. Cancer Causes Control 26:1393\u20131403","journal-title":"Cancer Causes Control"},{"key":"1530_CR37","doi-asserted-by":"publisher","unstructured":"Oskar S, Engmann NJ, Azus AR, Tehranifar P. Gestational diabetes, type II diabetes, and mammographic breast density in a U.S. racially diverse population screened for breast cancer. Cancer Causes Control 2018 298. 2018;29:731\u20136. doi:https:\/\/doi.org\/10.1007\/S10552-018-1048-6.","DOI":"10.1007\/S10552-018-1048-6"},{"key":"1530_CR38","doi-asserted-by":"publisher","unstructured":"Lee Argov EJ, Acheampong T, Terry MB, Rodriguez CB, Agovino M, Wei Y, et al. Independent and joint cross-sectional associations of statin and metformin use with mammographic breast density. Breast Cancer Res 2020 221. 2020;22:1\u20139. doi:https:\/\/doi.org\/10.1186\/S13058-020-01336-0.","DOI":"10.1186\/S13058-020-01336-0"},{"key":"1530_CR39","unstructured":"D\u2019Orsi CJ, Sickles EA, Mendelson EB, Morris EA et al. ACR BI-RADS\u00ae Atlas, Breast Imaging Reporting and Data System. 4th edition. Reston; 2013."},{"key":"1530_CR40","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1158\/1055-9965.EPI-17-0936","volume":"27","author":"GH Tang","year":"2018","unstructured":"Tang GH, Satkunam M, Pond GR, Steinberg GR, Blandino G, Sch\u00fcnemann HJ et al (2018) Association of metformin with breast cancer incidence and mortality in patients with type II diabetes: a GRADE-assessed systematic review and meta-analysis. Cancer Epidemiol Prev Biomarkers 27:627\u2013635. https:\/\/doi.org\/10.1158\/1055-9965.EPI-17-0936","journal-title":"Cancer Epidemiol Prev Biomarkers"},{"key":"1530_CR41","unstructured":"Chan KKW, Oza AM, Siu LL. The Statins as Anticancer Agents. 2003."},{"key":"1530_CR42","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1007\/s10549-011-1929-9","volume":"132","author":"CG Woolcott","year":"2012","unstructured":"Woolcott CG, Koga K, Conroy SM, Byrne C, Nagata C, Ursin G et al (2012) Mammographic density, parity and age at first birth, and risk of breast cancer: an analysis of four case-control studies. Breast Cancer Res Treat 132:1163\u20131171","journal-title":"Breast Cancer Res Treat"},{"key":"1530_CR43","doi-asserted-by":"crossref","unstructured":"van Gils CH, Hendriks JH, Otten JD, Holland R, Verbeek AL. Parity and mammographic breast density in relation to breast cancer risk: indication of interaction. Eur J Cancer Prev. 2000;9:105\u201311. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10830577. Accessed 14 Oct 2019.","DOI":"10.1097\/00008469-200004000-00006"},{"key":"1530_CR44","doi-asserted-by":"crossref","unstructured":"Martinson HA, Lyons TR, Giles ED, Borges VF, Schedin P. Developmental windows of breast cancer risk provide opportunities for targeted chemoprevention. 2013.","DOI":"10.1016\/j.yexcr.2013.04.018"},{"key":"1530_CR45","doi-asserted-by":"crossref","unstructured":"Terry MB, Michels KB, Brody JG, Byrne C, Chen S, Jerry DJ, et al. Environmental exposures during windows of susceptibility for breast cancer: a framework for prevention research. Breast Cancer Res. 2019;21.","DOI":"10.1186\/s13058-019-1168-2"},{"key":"1530_CR46","doi-asserted-by":"crossref","unstructured":"Slepicka PF, Cyrill SL, dos Santos CO. Pregnancy and breast cancer: pathways to understand risk and prevention. Trends Mol Med. 2019.","DOI":"10.1016\/j.molmed.2019.06.003"},{"key":"1530_CR47","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1038\/nm.2416","volume":"17","author":"TR Lyons","year":"2011","unstructured":"Lyons TR, O\u2019Brien J, Borges VF, Conklin MW, Keely PJ, Eliceiri KW et al (2011) Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2. Nat Med 17:1109\u20131116","journal-title":"Nat Med"},{"key":"1530_CR48","doi-asserted-by":"crossref","unstructured":"Hurwitz LM, Michels KA, Cook MB, Pfeiffer RM, Trabert B. Associations between daily aspirin use and cancer risk across strata of major cancer risk factors in two large U.S. cohorts. Cancer Causes Control. 2021;32:57\u201365.","DOI":"10.1007\/s10552-020-01357-2"},{"key":"1530_CR49","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1158\/1055-9965.EPI-20-1292","volume":"30","author":"M Cairat","year":"2021","unstructured":"Cairat M, Al Rahmoun M, Gunter MJ, Severi G, Dossus L, Fournier A (2021) Antiplatelet drug use and breast cancer risk in a prospective cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev 30:643\u2013652","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"1530_CR50","doi-asserted-by":"crossref","unstructured":"Hudson S, Vik Hjerkind K, Vinnicombe S, Allen S, Trewin C, Ursin G, et al. Adjusting for BMI in analyses of volumetric mammographic density and breast cancer risk. Breast Cancer Res. 2018;20.","DOI":"10.1186\/s13058-018-1078-8"}],"updated-by":[{"DOI":"10.1007\/s10552-022-01661-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,12,24]],"date-time":"2022-12-24T00:00:00Z","timestamp":1671840000000}}],"container-title":["Cancer Causes & Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-021-01530-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10552-021-01530-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-021-01530-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,24]],"date-time":"2022-12-24T11:11:02Z","timestamp":1671880262000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10552-021-01530-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,13]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["1530"],"URL":"https:\/\/doi.org\/10.1007\/s10552-021-01530-1","relation":{},"ISSN":["0957-5243","1573-7225"],"issn-type":[{"value":"0957-5243","type":"print"},{"value":"1573-7225","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,13]]},"assertion":[{"value":"31 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10552-022-01661-z","URL":"https:\/\/doi.org\/10.1007\/s10552-022-01661-z","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Acheampong was a post-doctoral researcher at Columbia University, funded by the T32 Cancer Epidemiology Training Grant from the National Institutes of Health, National Cancer Institute, during the completion of this study manuscript. Currently, she is employed by Bristol Myers Squibb. The authors declare that they have no competing financial interests related to this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}